Everything tagged "biotechnology" across the TickerSpark archives.
BridgeBio Pharma is transitioning into a commercial biotech, led by rapid Attruby sales growth and a late-stage pipeline. But losses, debt, and regulatory execution risk keep the stock at Hold.
Ionis is transitioning from a partnership-heavy biotech into a commercial company, led by TRYNGOLZA and DAWNZERA launches. The stock looks promising, but losses, negative free cash flow, and a rich valuation keep the rating at Hold.
argenx is scaling rapidly on VYVGART strength, with Q2 2026 product sales up 60% year over year and a deep autoimmune pipeline supporting the next leg of growth. The stock remains a Buy, though valuation is already reflecting much of the execution.
Moderna’s mRNA platform and respiratory franchise offer real upside, but revenue remains heavily concentrated in COVID and losses are still large. The stock trades well above fair value, making it a high-risk Sell despite promising late-stage pipeline assets.
Ascendis Pharma is transitioning into a scaled commercial biopharma, led by rapid YORVIPATH growth and a promising YUVIWEL launch. The stock still screens expensive, so the report lands on Hold despite strong revenue momentum.
Abivax is a catalyst-driven biotech centered on obefazimod, with long-term ulcerative colitis durability data and a cash runway into Q4 2027. The stock offers meaningful upside if Phase 3 execution holds, but the valuation already prices in a lot of success.
Summit Therapeutics is a high-risk, high-upside oncology story centered on ivonescimab and a November 2026 FDA decision. The stock offers meaningful regulatory upside, but the business still has no product revenue and remains dependent on one drug.
Roivant Sciences is a cash-rich biotech platform with a near-term brepocitinib launch and several late-stage catalysts, but valuation already reflects meaningful execution risk. The stock is a Hold as investors wait for commercial proof and clinical readouts.
Alnylam has crossed into profitable commercial-stage biotech, powered by AMVUTTRA and a fast-growing TTR franchise. Valuation is rich, but the company’s revenue growth, cash generation, and pipeline support a Buy rating.
OTLK's $5.81 million insider buying is a real vote of confidence, but the company is still funding an approved product with fresh equity. A $55 million stock-and-warrant offering, a 600 million share authorization and ongoing losses keep dilution ahead of durable commercial proof.
BioNTech is moving from fading COVID-19 vaccine revenue to a multi-product oncology pipeline, but near-term earnings remain weak. Its cash-rich balance sheet supports the transition, yet the stock still depends on late-stage clinical execution.
Vertex is executing well across cystic fibrosis, with ALYFTREK, CASGEVY, and JOURNAVX all contributing to growth while the renal pipeline and Crinetics deal broaden the story. The stock earns a Buy on durable cash generation and a fair value estimate of $560.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime